Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06218966
Other study ID # INCAT
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 15, 2024
Est. completion date June 1, 2024

Study information

Verified date September 2023
Source Sunnybrook Health Sciences Centre
Contact Trung Le, MD, PhD
Phone 416-480
Email trung.le@sunnybrook.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a feasibility study for a inner ear catheter which will be used to apply steroids to the inner ear. It will be used on nearly deaf patients during their surgery, when they receive an implant that will restore the hearing. Treatment with steroids will improve the maintenance of residual hearing, which will be tested during and after the surgery.


Description:

Study Device: The INCAT is an intracochlear catheter which is eligible in Canada for intracochlear drug delivery. Summary: 24 patients with moderate to profound hearing loss and indication for cochlear implantation will receive intracochlear treatment with steroids with an intracochlear catheter (INCAT) for hearing preservation prior to insertion of the cochlear implant array. Subjects will be considered for the study if they are 18 years of age or older and demonstrate a CNC word score in quiet of 60% or less in the ear to be implanted. Subjects will be followed for 6 months post-activation of the audio processor. Primary Objectives: Determination of feasibility of the intracochlear catheter INCAT and hearing preservation of residual hearing thresholds intra-, postoperatively, and long-term. Secondary Objectives: Assessment of quality of life, tinnitus and development of speech perception with the implant up to one year after implantation. Study Endpoint: Feasibility of using the INCAT and assessment of hearing preservation of residual hearing thresholds. Impedance field telemetry will help to assess hearing thresholds pre-, peri-, and postinsertion.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 24
Est. completion date June 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults, 18 years of age or older at the time of implantation - Moderate to profound hearing loss in the low frequencies and severe to profound hearing - Loss in the high frequencies, bilaterally as defined by (see Figure 4A and B below for example audiogram information) - Low-frequency pure tone average (PTA - 250, 500, and 1000 Hz) greater than 40 dB - High-frequencies not better than 65 decibels (3000 Hz - 8000 Hz) - Sensorineural hearing loss, demonstrated by an air-bone gap of less than or equal to 10 dB - Limited benefit from appropriately fit hearing aids, defined by consonant-nucleus-consonant (CNC) word score in quiet of 60% or less in the ear to be implanted and 70% or less in the non-implanted ear - CNC word score in quiet of greater than or equal to 10% in the ear to be implanted - Fluent in English - No radiological contraindications - Ability to undergo general anesthesia - Appropriate motivation and expectation levels - Stated willingness to comply with all study procedures for the duration of the study - Able to perform subjective hearing tests - Able to fill out questionnaires Exclusion Criteria: - Age less than 18 years - Not willing to provide informed consent - Unable to perform subjective hearing tests - Unable to fill out questionnaires - Previous unsensitivity to the investigated drug - Unable to follow the protocol for any reasons - Evidence that hearing loss is retrocochlear in origin - Active middle ear infection - Skin or scalp condition precluding use of external audio processor - Suspected cognitive impairment or organic brain dysfunction - History of prior use of a hearing implant

Study Design


Intervention

Device:
intracochlear catheter
intracochlear administration of steroids through the intracochlear catheter INCAT

Locations

Country Name City State
Canada Sunnybrook Health Sciences Centre Otolaryngology Department Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Sunnybrook Health Sciences Centre

Country where clinical trial is conducted

Canada, 

References & Publications (3)

Prenzler NK, Salcher R, Lenarz T, Gaertner L, Warnecke A. Dose-Dependent Transient Decrease of Impedances by Deep Intracochlear Injection of Triamcinolone With a Cochlear Catheter Prior to Cochlear Implantation-1 Year Data. Front Neurol. 2020 Apr 15;11:258. doi: 10.3389/fneur.2020.00258. eCollection 2020. — View Citation

Prenzler NK, Salcher R, Timm M, Gaertner L, Lenarz T, Warnecke A. Intracochlear administration of steroids with a catheter during human cochlear implantation: a safety and feasibility study. Drug Deliv Transl Res. 2018 Oct;8(5):1191-1199. doi: 10.1007/s13346-018-0539-z. — View Citation

Yildiz E, Gadenstaetter AJ, Gerlitz M, Landegger LD, Liepins R, Nieratschker M, Glueckert R, Staecker H, Honeder C, Arnoldner C. Investigation of inner ear drug delivery with a cochlear catheter in piglets as a representative model for human cochlear pharmacokinetics. Front Pharmacol. 2023 Mar 9;14:1062379. doi: 10.3389/fphar.2023.1062379. eCollection 2023. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Pure tone average with air and bone conduction air and bone conduction of the frequencies 0.25, 0.5, 1, 2, 4, 6, 8 kHz 12 Months
Primary speech audiometry CNC, AzBio, HINT 12 months
Primary Impedance Impedance testing for all electrodes 12 months
Primary ECAPs electrically evoked compound action potential testing for all electrodes 12 months
Primary ECochG electrocochleargraphy 12 months
Secondary Tinnitus Assessment of tinnitus with Tinnitus Handicap Inventory, which is a 25-item self-report measure to determine perceived tinnitus handicap severity 12 Months
See also
  Status Clinical Trial Phase
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Completed NCT04601909 - FX-322 in Adults With Age-Related Sensorineural Hearing Loss Phase 1
Active, not recruiting NCT04479761 - Sensory Integration of Auditory and Visual Cues in Diverse Contexts N/A
Recruiting NCT05043207 - A Study Protocol for the Validation of UAud in a Clinical Setting. N/A
Recruiting NCT04070937 - Correlation of Radiological Lesions With Vestibular Function in Patients With Bilateral Vestibulopathy
Recruiting NCT04066270 - Inventory of Radiological and Vestibular Function in Cochlear Implant Candidates
Completed NCT03512951 - Subjective Evaluation of a Sound Processing Method for Hearing Aids on Auditory Distance Perception N/A
Active, not recruiting NCT05855005 - Direct-to-Consumer Hearing Aids and Listening Effort N/A
Recruiting NCT05599165 - Speech Perception in Bimodal Hearing N/A
Completed NCT05101083 - Speech Intelligibility in Quiet and Noise for New vs. Legacy Hearing Aids N/A
Completed NCT05521308 - Investigating Hearing Aid Frequency Response Curves N/A
Completed NCT05072457 - Benefit of Assistive Listening Device for Lateralization N/A
Recruiting NCT05776459 - Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) Phase 2
Completed NCT05086276 - FX-322 in Adults With Acquired Sensorineural Hearing Loss Phase 2
Recruiting NCT06058767 - Preschool Hearing Screening N/A
Completed NCT05180630 - Sound Quality Comparisons With Different Hearing Aid Couplings and Venting Systems N/A
Completed NCT03613909 - Acceptance of the CP950 Sound Processor N/A
Active, not recruiting NCT03352154 - Long Latency Auditory Evoked Potentials (P300) Outcomes in Patients With Unilateral Cochlear Implants N/A
Completed NCT04629664 - FX-322 in Adults With Severe Sensorineural Hearing Loss Phase 1
Completed NCT05052944 - Single-sided Deafness and Cochlear Implantation